Physician

Subhash Proothi, MD

Study Coordinator

Cynthia Evancho
484-658-2534

cynthia.evancho@sluhn.org

Close

Synopsis:  A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma/ Waldenström Macroglobulinemia/ Mantle Cell Lymphoma/ or Marginal Zone Lymphoma Intolerant of Prior Treatment with Ibrutinib

Close

• Is ≥18 years of age, at the time of signing the informed consent
• CLL or SLL, MCL, MZL, or WM with prior documented intolerance (by protocol defined criteria) of ibrutinib or acalabrutinib +/- ibrutinib (at least 4 weeks of prior tx)
• Patients must not have document PD during ibrutinib and/or acalabrutinib treatment- ECOG PS 0-2- No known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation

Close